(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 4.32% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.89%.
Merck & Co's revenue in 2025 is $63,616,000,000.On average, 7 Wall Street analysts forecast MRK's revenue for 2025 to be $162,254,221,462,697, with the lowest MRK revenue forecast at $161,853,629,489,100, and the highest MRK revenue forecast at $163,111,088,491,014. On average, 7 Wall Street analysts forecast MRK's revenue for 2026 to be $171,062,211,848,660, with the lowest MRK revenue forecast at $166,360,614,528,329, and the highest MRK revenue forecast at $176,348,490,263,022.
In 2027, MRK is forecast to generate $180,532,409,523,957 in revenue, with the lowest revenue forecast at $173,817,568,962,162 and the highest revenue forecast at $189,591,736,847,744.